Table 1. Baseline characteristics.
| Characteristics | Number |
|---|---|
| Sex, n (%) | |
| Male | 10 (83.3) |
| Female | 2 (16.7) |
| Mean age (years) | 55.9±8.4 |
| Etiology, n (%) | |
| Hepatitis B virus | 12 (100.0) |
| Hepatitis C virus | 0 |
| Unknown | 0 |
| BCLC stage, n (%) | |
| A | 0 |
| B | 0 |
| C | 12 (100.0) |
| PVTT grade, n (%) | |
| A | 3 (25.0) |
| B | 9 (75.0) |
| C | 0 |
| Extrahepatic metastasis, n (%) | 7 (58.3) |
| Lung | 3 (25.0) |
| Lymph node | 4 (33.3) |
| Bone | 2 (16.7) |
| Paranephros | 1 (8.3) |
| Pleura | 1 (8.3) |
| Initial dose of lenvatinib, n (%) | |
| 12 mg | 4 (33.3) |
| 8 mg | 8 (66.7) |
| Reduced initial dose of lenvatinib | 1 (8.3) |
BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus.